-
公开(公告)号：US11826374B2
公开(公告)日：2023-11-28
申请号：US17686807
申请日：2022-03-04
IPC分类号： A61K31/56 , A61K31/045 , A61K36/185 , A61L15/44 , A61L26/00 , A61K9/00 , A61K9/06 , A61K9/107 , A61K9/12 , A61K45/06
CPC分类号： A61K31/56 , A61K31/045 , A61K36/185 , A61L15/44 , A61L26/0066 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K9/122 , A61K45/06 , A61K2236/00 , A61L2300/30
摘要： The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing.
-
公开(公告)号：US11826319B2
公开(公告)日：2023-11-28
申请号：US17022296
申请日：2020-09-16
申请人： NuvOx Pharma LLC
发明人： Evan C. Unger , Edmund Marinelli
IPC分类号： A61K31/02 , B02C19/18 , A61K9/107 , A61M5/178 , A61B8/08 , A61M39/10 , B06B1/10 , A61K9/00 , B82Y40/00
CPC分类号： A61K31/02 , A61B8/481 , A61K9/1075 , A61M5/178 , A61M39/10 , B02C19/18 , B06B1/10 , A61K9/0019 , A61M2205/02 , A61M2205/8275 , B82Y40/00
摘要： The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).
-
公开(公告)号：US20230364172A1
公开(公告)日：2023-11-16
申请号：US18317436
申请日：2023-05-15
申请人： Syncotrance, LLC
发明人： Mikhail MALAKHOV
CPC分类号： A61K36/28 , A61K9/1075
摘要： A method of manufacture of a Kratom-derived formulation for oral, and buccal delivery comprising Mitragyna speciosa-derived compounds (e.g., mitragynine) formulated with phospholipids is disclosed. Kratom-derived extracts have dramatically improved organoleptic properties and enhanced bioavailability when formulated with phospholipids as compared to standard extracts. Also disclosed herein are methods of transmucosal administration of the formulation having phospholipids with Kratom-derived substances. The methodology is directly applicable to other botanical extracts as well as other substances requiring improved organoleptic properties.
-
公开(公告)号：US20230355640A1
公开(公告)日：2023-11-09
申请号：US18312162
申请日：2023-05-04
IPC分类号： A61K31/192 , A61K9/12 , A61K47/44 , A61K31/573 , A61K9/00 , A61K47/26 , A61K47/14 , A61K9/107 , A61K31/4436 , A61K45/06 , A61K9/06
CPC分类号： A61K31/573 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K9/12 , A61K31/192 , A61K31/4436 , A61K45/06 , A61K47/14 , A61K47/26 , A61K47/44
摘要： Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.
-
公开(公告)号：US20230355547A1
公开(公告)日：2023-11-09
申请号：US18246234
申请日：2021-09-24
IPC分类号： A61K31/07 , A61K41/10 , A61K9/107 , A61K47/44 , A61K47/22 , A61K31/122 , A61K31/355 , A61K31/593 , A61K47/26 , A61K47/34 , A61K47/12 , A61K9/00 , A61K45/06
CPC分类号： A61K31/07 , A61K41/10 , A61K9/1075 , A61K47/44 , A61K47/22 , A61K31/122 , A61K31/355 , A61K31/593 , A61K47/26 , A61K47/34 , A61K47/12 , A61K9/0029 , A61K45/06
摘要： The invention relates to a medical product for preventing or correcting vitamin A deficiency in a patient comprising a lipid emulsion in a flexible container, the lipid emulsion comprising (a) vitamin A in the lipid phase of the lipid emulsion, (b) optionally additionally vitamin D, vitamin E and/or vitamin K in the lipid phase of the lipid emulsion, and (c) no more than 1.5 ppm dissolved oxygen (DO), (d) wherein the pH of the lipid emulsion is from 5 to 9.
-
公开(公告)号：US11806407B2
公开(公告)日：2023-11-07
申请号：US17045469
申请日：2019-04-05
发明人： Matthew J. Webber , Lei Zou
IPC分类号： A61K47/69 , A61P35/04 , A61K9/00 , A61K9/06 , A61K9/107 , A61K31/167 , A61K31/573 , A61K31/704
CPC分类号： A61K47/6903 , A61K9/0024 , A61K9/06 , A61K9/1075 , A61K31/167 , A61K31/573 , A61K31/704 , A61P35/04
摘要： Described herein are compositions and methods for a novel drug delivery platform using affinity homing. Also disclosed herein are a drug delivery system, methods for using the novel drug delivery platform and a kit.
-
公开(公告)号：US11806378B1
公开(公告)日：2023-11-07
申请号：US18125106
申请日：2023-03-22
发明人： Heba Ibrahim Abd El-Moaty , Hairul-Islam Mohamed Ibrahim , Zainab Hussain Almansour , Rabab Salem Hamad
摘要： A therapeutic composition including phenolic compounds derived from Opuntia littoralis (OL) includes an extract of Opuntia littoralis and lutein. The Opuntia littoralis extract can be formed by extracting an Opuntia littoralis plant powder with an alcohol to provide an Opuntia littoralis alcohol extract (OLAE) including the phenolic compounds. In an embodiment, the therapeutic composition can be effectively used as an analgesic for the treatment of pain, as an anti-inflammatory, as a treatment for immunological disorders, and/or as a treatment for oxidant conditions.
-
公开(公告)号：US11806330B2
公开(公告)日：2023-11-07
申请号：US16366596
申请日：2019-03-27
发明人： Yrr Morch , Einar Sulheim , Kjersti Flatmark , Karianne Giller Fleten , Per Stenstad , Heidi Johnsen , Ruth Schmid
CPC分类号： A61K31/337 , A61K9/0019 , A61K9/1075 , A61K9/1641 , A61K9/5138 , A61K9/5146 , A61K9/5192 , A61K47/60 , A61P35/04 , B82Y5/00
摘要： Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.
-
99.发明授权公开(公告)号：US11806318B2
公开(公告)日：2023-11-07
申请号：US17368366
申请日：2021-07-06
IPC分类号： A61K39/35 , A61K9/107 , A61K9/00 , A61K47/22 , A61K47/44 , A61K47/26 , A61K9/14 , A61K39/00 , A61K39/29 , C12N7/00
CPC分类号： A61K39/35 , A61K9/0043 , A61K9/1075 , A61K9/143 , A61K39/292 , A61K47/22 , A61K47/26 , A61K47/44 , C12N7/00 , A61K2039/543 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/57 , C12N2730/10134
摘要： The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
-
公开(公告)号：US20230346690A1
公开(公告)日：2023-11-02
申请号：US18345760
申请日：2023-06-30
发明人： David W. OSBORNE
IPC分类号： A61K9/00 , A61K47/69 , A61P17/06 , A61K9/06 , A61K9/107 , A61K31/122 , A61K31/17 , A61K31/194 , A61K31/366 , A61K31/44 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K31/60 , A61K47/10 , A61K47/14 , A61K47/24
CPC分类号： A61K9/0014 , A61K47/6903 , A61P17/06 , A61K9/06 , A61K9/107 , A61K31/122 , A61K31/17 , A61K31/194 , A61K31/366 , A61K31/44 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K31/60 , A61K47/10 , A61K47/14 , A61K47/24 , A61K45/06
摘要： Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.
-
-
-
-
-
-
-
-
-
搜索结果
5952 条记录 (耗时 0.046 秒)
